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Background:  Intramyocardial injection of autologous bone marrow mononuclear cells (BMMC) is believed to be a promising method for the 
treatment of patients with chronic ischemic heart disease. The aim of this study was to evaluate long-term results of intramyocardial bone marrow 
cell injection in patients with severe ischemic heart failure.
Methods:  109 patients with chronic myocardial infarction and end-stage chronic heart failure were randomized into two groups: 55 patients 
received intramyocardial BMMC injection and 54 were treated with medicamentous therapy. The NOGA system (Biosense-Webster) was used to 
administer 41 ± 16 x 106 BMMC into the infarction border zone.
Results:  None of the patients developed periprocedural complications following BMMC injections. The injections led to improvement of CCS class 
(3.1 ± 0.4 vs 1.6 ± 0.6 after 6 months and 1.6 ± 0.4 after 12 months; p=0.001) and NYHA functional class (3.3 ± 0.2 vs 2.3 ± 0.2 after 6 months 
and 2.5 ± 0.1 after 12 months; p=0.006). The same characteristics in patients given medicamentous therapy remained unaltered. Left ventricular 
ejection fraction increased significantly in the BMMC group (27.8 ± 3.4% vs 32.3 ± 4.1%; p=0.04) while it tended to decrease in the control group 
(26.8 ± 3.8% vs 25.2 ± 4.1%; p=0.61). Summed rest score improved in the BMMC group after 12 months (30.2 ± 5.6 vs 27.8 ± 5.1; p=0.032). The 
improvement of stress score was more noticeable (34.5 ± 5.4 vs 28.1 ± 5.2; p=0.016). Neither stress nor rest score changed in patients on medical 
therapy. In BMMC group 6 (10.9%) patients died at 12 month follow up compared with 21 (38.9%) in control group (Log-Rank test, p=0.0007).
Conclusions:  Intramyocardial bone marrow cell transplantation to patients with ischemic heart failure is a safe procedure that improves clinical 
symptoms and has beneficial effect on LV function.
